Global medical beauty company JDBIO Co., Ltd. (CEO Kim Jin-Dong) continues its steady growth with a focus on international markets.
JDBIO has secured a strong presence in major overseas markets including the United States, Europe, and Russia, gaining recognition for its brand power, product stability, and reliability.
In 2024, the company achieved KRW 90.64 billion in revenue, marking a 40% increase from the previous year. This follows KRW 20.7 billion in 2022 and KRW 64.8 billion in 2023, setting new record-highs for three consecutive years.
In 2025, JDBIO is aiming for over KRW 120 billion in total revenue and $70 million in exports. To reach this goal, the company has established a Global Division, is reinforcing the competitiveness of its core brands such as RICHESSE™, DEMEI™, and OneFill™, launching new business initiatives, and actively entering the Latin American market. In particular, the company is expanding its sales operations in the region to boost revenue and diversify its global network.
In addition, JDBIO plans to strengthen its partnership with PharmaResearch, anticipating over 100% growth in Rejuran cosmetics in the Chinese market compared to the previous year.
CEO Kim Jin-Dong stated,
“JDBIO has achieved outstanding results in overseas markets based on technological innovation and customer trust. We are expecting sales to exceed KRW 120 billion in 2025. Looking ahead, we aim to further enhance our brand competitiveness, differentiate through product strategy, and continue expanding into broader global markets.”
Meanwhile, JDBIO is preparing to launch a range of new products tailored to global demand. The company is enhancing collaboration with international distribution partners and plans to actively engage in major exhibitions and marketing initiatives to ensure successful global entry of its new offerings.
Source: JDBIO to Aggressively Enter Latin American Market in 2025… “Targeting KRW 120 Billion in Global Sales”, Korea Economic Daily, April 10, 2025.